Tara Brancroft

“So thanks for hosting this call and taking our questions. I was hoping maybe you could give us any more detail or thoughts or feelings that you have on a regulatory update.”

“So thanks for hosting this call and taking our questions. I was hoping maybe you could give us a little any more detail or thoughts or feelings that you have on a regulatory update.”

“So I want to follow up on one of the first questions that was asked. So I'm curious in what ways you think you could improve access and adoption as a second to market relative to backs, especially as it comes to pricing.”

“So I just have a follow-up from Moet's question before that was helpful to hear about label differentiation, but maybe can you tell us more about how you'll react to back pricing, especially, you know, when it comes to your pricing strategy?”

“So I'm curious, based on the FDA communications that you've had and received, what's your level of confidence that the long-term follow-up from this trial would suffice for this post-marketing requirement that's labeled by the language in the label?”